By 2030, a diabetes prevention and treatment system will enable over 60% of residents aged 18 and above to be aware of the disease. By then, the coverage rate of standardized management services for type 2 diabetes patients at the primary level will exceed 70%, according to the documents released by multiple departments including the National Health Commission (NHC).

 

With the development of the economy and society, chronic diseases have become an important factor hindering the improvement of healthy life expectancy in China, according to the NHC.

 

Data shows that over 80% of deaths in China were caused by major chronic diseases, such as cardiovascular and cerebrovascular diseases, cancer, diabetes and chronic respiratory diseases.

 

Currently, China has over 30 million diabetic patients aged 65 and above. 

 

In recent years, China has established the world's largest disease and health risk surveillance network, and the premature mortality rate of major chronic diseases has decreased from 18.5% in 2015 to 15.3% in 2021.

 

 

Clinical Significance of Diabetes Tests & Diagnosis

 

Some 537 million adults (aged 20-79 years) globally had diabetes in 2021 (1 in 10 people). This number is expected to rise to 643 million by 2030 and 783 million by 2045.

 

During this period, the world population is estimated to grow by 20%, while the number of people with diabetes is estimated to increase by 46%. 

 

We need rapid assessment in the early stages of the disease, and accurate intervention and scientific management can minimize disease progression or adverse prognosis, with glycated haemoglobin (HbA1c), insulin (INS), and C-peptide (C-P) diabetes-related markers playing a particularly important role in prediabetes as well as monitoring during the disease.

 

These indicators and test results are important for early diagnosis, timely treatment and effective control of type 2 diabetes, helping to improve patients' quality of life and prevent diabetes-related complications. 

 

For patients who have been diagnosed with diabetes, regular monitoring of blood glucose, HbA1c, insulin and C-peptide is also important for managing the disease, assessing the effectiveness of treatment and adjusting the treatment plan.

 

 

Latest Trends in International and Chinese Branded Diabetes Testing

 

On 8 August, Abbott announced a global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

 

On 9 July, Roche announced that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. 

 

Sinocare acquired Nipro Diagnostic Inc. (now renamed as Trividia Health Inc.) and PTS Diagnostics Inc. in 2016 and has been working on improving the quality of life of users around the world and providing fast, accurate, easy, and portable medical equipment and information management systems for patients with chronic diseases and medical practitioners.